SO
NRIX icon

STRS Ohio’s Nurix Therapeutics NRIX Stock Holding History

STRS Ohio’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,800
Closed -$222K – 1985
2024
Q4 		$222K Hold
11,800
– – ﹤0.01% 1471
2024
Q3 		$265K Sell
11,800
-16,900
-59% -$383K ﹤0.01% 1480
2024
Q2 		$599K Buy
+28,700
New +$447K ﹤0.01% 1104
2021
Q2 		– Sell
-2,200
Closed -$68K – 2356
2021
Q1 		$68K Sell
2,200
-600
-21% -$22.7K ﹤0.01% 2002
2020
Q4 		$92K Hold
2,800
– – ﹤0.01% 1902
2020
Q3 		$97K Buy
+2,800
New +$70.6K ﹤0.01% 1852

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

STRS Ohio's NRIX Position: Q1 2025 in Review

STRS Ohio sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 11,800 shares — an estimated $222K sold.

STRS Ohio first reported a position in NRIX in Q3 2020 and held it in 6 quarters. The position peaked at $599K in Q2 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • STRS Ohio reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • STRS Ohio sold 11,800 Nurix Therapeutics shares in Q1 2025, an estimated $222K.
  • STRS Ohio first reported a position in Nurix Therapeutics in Q3 2020 and held it in 6 quarters.
  • STRS Ohio's Nurix Therapeutics position peaked at $599K in Q2 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on STRS Ohio's 13F filing for Q1 2025, filed 28 May 2025.